Iterum Therapeutics plc
Iterum Therapeutics plc (ITRM) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
itrm · stock forecast · 1 analysts (3M) · FMP · updated Apr 1, 2026
Analyst Rating & Consensus
Based on 1 Wall Street analysts in the past 3 months
Hold
1 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.02
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $0.02 | ↑ 0.00% |
1-day model range: $0.02–$0.02. Peak: $0.02 (+0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ITRM · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-30 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2024-08-15 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-06-21 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-05-31 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-05-14 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-04-30 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-04-01 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-03-06 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-02-07 | HC Wainwright & Co. | Upgrade ↑ | Neutral→Buy |
Wall Street analysts have recently issued updated ratings on Iterum Therapeutics plc (ITRM) stock. Of the recent 9 rating actions, 1 were upgrades and 1 were downgrades. 1 analysts currently cover ITRM.
Analyst Recommendation Trends
ITRM analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
↓ 97.8% YoY
Revenue Next Year
$9M
↑ 947.7% YoY
EPS This Year
$-0.66
EPS Next Year
$-0.31
↓ 53.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast ITRM EPS of $-0.66 for the current fiscal year, based on estimates from 1 analysts. The ITRM revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ITRM stock forecast is supported by two independent data sources: analyst consensus ratings from 1 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ITRM price target is $0.00 (+0.0% upside), with an analyst consensus of Hold.
The ITRM short-term stock prediction for tomorrow is $0.02 (+0.00%).
Iterum Therapeutics plc trades on NASDAQ under the ticker ITRM. The ITRM stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 0% of covering analysts.
Frequently asked questions
ITRM forecast · 8 questionsAccording to 1 Wall Street analysts, the average 12-month ITRM price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.02.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.